Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Avanafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avanafil SCHEMBL29372265 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL118799 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL30446867 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL31143663 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL1171811 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL30335524 | 1.00 | PDE5A (1.00) | PDE5A | |
| SCHEMBL29144167 | 0.97 | PDE5A (0.94) | PDE5A | |
| Avanafil SCHEMBL28462779 | 0.96 | PDE5A (0.92) | PDE5A | |
| Avanafil SCHEMBL28462777 | 0.96 | PDE5A (0.92) | PDE5A | |
| SCHEMBL28723744 | 0.95 | PDE5A (0.90) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20210378964-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC | 2021-12-09 | — | — | US | disclosed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-20200030239-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC (F/K/A VIVUS, INC.) | 2020-01-30 | — | — | US | disclosed |
| US-20190133955-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10028916-B2 | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use | VIVUS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028916-B2 | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use | VIVUS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160331687-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC (F/K/A VIVUS, INC.) | 2016-11-17 | — | — | US | disclosed |
| US-20160331687-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC (F/K/A VIVUS, INC.) | 2016-11-17 | — | — | US | disclosed |
| WO-2015177807-A1 | A PROCESS FOR THE PREPARATION OF AVANAFIL AND ITS NOVEL INTERMEDIATES | WANBURY LTD. (IN) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015001567-A1 | PROCESS FOR THE PREPARATION OF (S)-4-[(3-CHLORO-4-METHOXYBENZYL)AMINO]-2-[2- (HYDROXYMETHYL)-1-PYRROLIDINYL]-N-(2-PYRIMIDINYL METHYL-5-PYRIMIDINE CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030239-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | PDE7A, PDE3A, PDE9A | PDE5A 6/4885 |
| US-20190133955-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | PDE7A, PDE3A, PDE9A | PDE5A 6/4885 |
| US-10028916-B2 | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use | PDE7A, PDE3A, PDE9A | PDE5A 6/4885 |
| US-20160331687-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | PDE7A, PDE3A, PDE9A | PDE5A 6/4885 |
| US-20210378964-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | PDE7A, PDE3A, PDE9A | PDE5A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.